- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03330028
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
The goal of this clinical research study is to find the highest tolerable dose of paclitaxel that can be given as hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with gastric or gastroesophageal cancer. HIPEC is a system in which heated chemotherapy is delivered directly inside the abdomen during surgery. In this study, paclitaxel is being combined with mitomycin and cisplatin to see if this study drug combination can help to control the disease.
This is an investigational study. Mitomycin, cisplatin, and paclitaxel are FDA-approved and commercially available for the treatment of gastric and gastroesophageal cancer. It is investigational to give these drugs by HIPEC.
The study doctor can describe how the study drugs and HIPEC are designed to work.
Up to 48 participants will be enrolled in this study. All will take part at MD Anderson.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Groups:
If participant is found to be eligible to take part in this study, participant will be assigned to a dose level of paclitaxel based on when participant joins this study. Up to 8 dose levels of paclitaxel will be tested. Up to 6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of paclitaxel is found.
All participants will receive the same dose level of mitomycin and cisplatin.
HIPEC Treatment and Study Visits:
On the day of HIPEC treatment, participant will receive heated mitomycin, cisplatin, and paclitaxel as a liquid that is injected through 3 to 4 small incisions in participant's abdomen over about 1 hour. Heated mitomycin, cisplatin, and paclitaxel will be delivered through plastic tubing that is connected to a pump into the abdominal cavity. The pump pushes the heated drugs into the abdominal cavity and then pulls it out and recirculates the drugs. The skin of the abdominal cavity is temporarily closed during this procedure. A pump will be used to pump the heated drugs in and out of the abdominal cavity over 60 minutes while the surgeon gently presses on the abdominal wall so the drugs can reach all areas in the abdominal cavity. After 60 minutes, the drugs are removed and the abdominal cavity will be washed. The remaining fluid will be removed before the surgeon closes the abdominal cavity with stitches.
Additionally, participant will be given standard drugs to help decrease the risk of side effects. Participant may ask the study staff for information about how the drugs are given and their risks.
Participant will remain in the hospital for 3-7 days after treatment.
While participant is in the hospital after surgery, blood (about 2-3 tablespoons) may be drawn for routine tests at any time that the study doctor thinks it is needed.
One (1) time between 2-6 weeks after HIPEC Treatment:
- Participant will have a physical exam.
- Blood (about 2-3 tablespoons) will be drawn for routine tests.
Follow-Up Visits:
Participant will have routine clinic visits or participant will be called every 6 months after the HIPEC procedure. Participant will be asked about any other cancer treatments participant may be receiving. If participant is called, these calls should last about 5-10 minutes. If participant stopped the study early, the study doctor may ask participant to return to the clinic for extra CT scans, PET scan, or MRIs during the follow-up period.
Participant will have a CT scan, PET scan, or MRI of participant's chest, abdomen, and pelvis every 6 months for 5 years after surgery to check the status of the disease.
Length of Study Participation:
Participant will be on study for about 5 years after participant's last procedure (HIPEC or surgery). Participant will be taken off study early if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.
Participation on the study will be over after the follow-up visits.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and above. There will be no upper age restriction.
- Eastern Cooperative Oncology Group (ECOG) performance status </= 2.
- Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.
- Adequate renal, and bone marrow function: a. Leukocytes >= 3,000/uL b. Absolute neutrophil count >= 1,500/uL c. Platelets >= 60,000/Ul d. Serum creatinine <= 1.5 mg/dL
- Distant Metastatic Disease of peritoneum: a. Positive peritoneal cytology b. Carcinomatosis on diagnostic laparoscopy or laparotomy.
- Completion of preoperative systemic chemotherapy.
Exclusion Criteria:
- Infections such as pneumonia or wound infections that would preclude protocol therapy.
- Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.
- Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure.
- Subjects deemed unable to comply with study and/or follow-up procedures.
- Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)
Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
|
10 mg by vein approximately 60 minutes before Paclitaxel.
Other Names:
50 mg by vein approximately 60 minutes before Paclitaxel.
Other Names:
20 mg by vein approximately 60 minutes before Paclitaxel.
Other Names:
Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Other Names:
Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Other Names:
Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen. Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Time Frame: 3 to 7 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion
|
MTD selected based on isotonic regression as specified per methods by Liu and Yuan.
|
3 to 7 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion
|
Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Time Frame: Within 21 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion
|
Dose limiting toxicity (DLT) graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) by organ system.
DLT defined as any grade III/IV non-hematologic or neutropenia-associated (infection or fever treated in the hospital) toxicity attributable to this therapy.
|
Within 21 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brian D. Badgwell, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Gastric cancer
- Cisplatin
- Hyperthermic intraperitoneal chemotherapy
- HIPEC
- Dexamethasone
- Paclitaxel
- Famotidine
- Taxol
- Decadron
- Diphenhydramine
- Mitomycin-C
- Platinol-AQ
- Platinol
- CDDP
- Mitomycin
- Gastroesophageal cancer
- Diseases of oesophagus stomach and duodenum
- Adenocarcinoma of the stomach or gastroesophageal junction
- Benadryl
- Pepcid
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Wounds and Injuries
- Gastrointestinal Diseases
- Body Temperature Changes
- Heat Stress Disorders
- Carcinoma
- Adenocarcinoma
- Hyperthermia
- Fever
- Esophageal Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Sensory System Agents
- Anesthetics
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Antibiotics, Antineoplastic
- Anti-Ulcer Agents
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Histamine H2 Antagonists
- Dexamethasone
- Paclitaxel
- Cisplatin
- Diphenhydramine
- Promethazine
- Mitomycins
- Mitomycin
- Famotidine
Other Study ID Numbers
- 2017-0232
- NCI-2018-01035 (Registry Identifier: NCI CTRP- Clinical Trials Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diseases of Oesophagus Stomach and Duodenum
-
Shandong Branden Med.Device Co.,LtdCompletedUnspecified Disorder of Stomach and DuodenumChina
-
Vitkovice HospitalUnknownOther Specified Disorders of Esophagus, Stomach or DuodenumCzech Republic
-
BayerCompletedPrevention of Oesophagus Cancer and Stomach CancerUnited Kingdom
-
Royal Marsden NHS Foundation TrustEli Lilly and Company; AstraZeneca; Clovis Oncology, Inc.; MedImmune LLCRecruitingAdenocarcinoma of the Stomach | Adenocarcinoma of the Oesophagus | Adenocarcinoma of the Gastro-oesophageal JunctionUnited Kingdom
-
Liverpool University Hospitals NHS Foundation TrustUniversity Hospital Southampton NHS Foundation TrustCompletedTumor of Esophagus, Stomach and DuodenumUnited Kingdom
-
Oregon Health and Science UniversityCompletedInjury of Duodenum | Pancreatic InjuryUnited States
-
Markus M. HeissUniversity of Witten/Herdecke; VAC Stent GmbH; Möller Medical GmbH; MicroTech Europe...Recruiting
-
Royal Marsden NHS Foundation TrustCompletedAdenocarcinoma of OesophagusUnited Kingdom
-
Texas Tech University Health Sciences Center, El...CompletedPancreatic or Peripancreatic Lesions | Lesions in the Esophagus, Stomach, Duodenum or Rectum | Mediastinal ( Chest) Masses | Enlarged Lymph NodesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedStomach Neoplasms | Oesophageal Junction Cancer | Lower Oesophagus CancerFrance
Clinical Trials on Dexamethasone
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Universidade Federal de PernambucoCompletedDiabetic Macular EdemaBrazil
-
Shanghai Jiao Tong University Affiliated Sixth...CompletedAnalgesia | Time | Brachial Plexus Block | Shoulder Surgery | Dexamethasone | Intravenous Drug UsageChina
-
Poznan University of Medical SciencesRecruitingWrist Injuries | Hand Injuries | Hand Injuries and Disorders | Hand Disease | Wrist DiseasePoland
-
University of California, San FranciscoCompletedOral Lichen Planus | Pemphigus Vulgaris | Mucous Membrane Pemphigoid | Chronic Graft-versus-host-diseaseUnited States
-
University of BelgradeCompleted